StockData
Kairos Pharma, LTD. logo

Kairos Pharma, LTD. (KAPA) stock

KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.40−0.01 (-1.70%)

Close on Nov 17, 2026Market cap $1.49MP/E –Yield –

Kairos Pharma r&d expenses

Research and development expenses are spending on new products and technology.

Kairos Pharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.73M, up 54.5% year over year. For fiscal 2025 it was $2.14M, up 415.7% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.14M+415.7%
FY2024Dec 31, 2024$414.00K+404.9%
FY2023Dec 31, 2023$82.00K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$892.00K+46.7%
Q2 FY2026Jun 30, 2026$619.00K+24.8%
Q1 FY2026Mar 31, 2026$684.00K+38.7%
Q4 FY2025Dec 31, 2025$538.00K+212.8%
Q3 FY2025Sep 30, 2025$608.00K+4242.9%
Q2 FY2025Jun 30, 2025$496.00K+687.3%
Q1 FY2025Mar 31, 2025$493.00K+198.8%
Q4 FY2024Dec 31, 2024$172.00K+2357.1%
Q3 FY2024Sep 30, 2024$14.00K-57.6%
Q2 FY2024Jun 30, 2024$63.00K–
Q1 FY2024Mar 31, 2024$165.00K–
Q4 FY2023Dec 31, 2023$7.00K–
Q3 FY2023Sep 30, 2023$33.00K–

More Kairos Pharma figures

See a number that looks wrong?